Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rosa I Gallagher

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Molecular Diagnosis & Therapy|November 1, 2014
Reverse phase protein arrays: mapping the path towards personalized medicineRosa I Gallagher, Virginia Espina
Methods in Molecular Biology (Clifton, N.J.)|November 15, 2011
Laser capture microdissection: Arcturus(XT) infrared capture and UV cutting methodsRosa I Gallagher, Steven R Blakely, Lance A Liotta, et al.
Methods in Molecular Biology (Clifton, N.J.)|March 4, 2011
Reverse phase protein microarrays: fluorometric and colorimetric detectionRosa I Gallagher, Alessandra Silvestri, Emanuel F Petricoin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 4, 2025
Immune and Growth Factor Signaling Pathways Are Associated with Pathologic Complete Response to an Anti-Type I Insulin-like Growth Factor Receptor Regimen in Patients with Breast CancerEmmanuel F Petricoin, Denise M Wolf, Christina Yau, et al.
Breast Cancer Research : BCR|September 19, 2013
An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer modelsWenle Xia, Emanual F Petricoin, Sumin Zhao, et al.
Journal of Medical Imaging (Bellingham, Wash.)|January 4, 2018
Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIALAdam Olshen, Denise Wolf, Ella F Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 28, 2021
Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti-PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast CancerPaula I Gonzalez-Ericsson, Julia D Wulfkhule, Rosa I Gallagher, et al.
Blood Advances|October 17, 2017
Microenvironmental agonists generate <i>de novo</i> phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCLKallesh D Jayappa, Craig A Portell, Vicki L Gordon, et al.
NPJ Breast Cancer|October 21, 2020
Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trialDenise M Wolf, Christina Yau, Julia Wulfkuhle, et al.
Plos One|April 28, 2010
Malignant precursor cells pre-exist in human breast DCIS and require autophagy for survivalVirginia Espina, Brian D Mariani, Rosa I Gallagher, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Molecular Diagnosis & Therapy|November 1, 2014
Reverse phase protein arrays: mapping the path towards personalized medicineRosa I Gallagher, Virginia Espina
Methods in Molecular Biology (Clifton, N.J.)|November 15, 2011
Laser capture microdissection: Arcturus(XT) infrared capture and UV cutting methodsRosa I Gallagher, Steven R Blakely, Lance A Liotta, et al.
Methods in Molecular Biology (Clifton, N.J.)|March 4, 2011
Reverse phase protein microarrays: fluorometric and colorimetric detectionRosa I Gallagher, Alessandra Silvestri, Emanuel F Petricoin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 4, 2025
Immune and Growth Factor Signaling Pathways Are Associated with Pathologic Complete Response to an Anti-Type I Insulin-like Growth Factor Receptor Regimen in Patients with Breast CancerEmmanuel F Petricoin, Denise M Wolf, Christina Yau, et al.
Breast Cancer Research : BCR|September 19, 2013
An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer modelsWenle Xia, Emanual F Petricoin, Sumin Zhao, et al.
Journal of Medical Imaging (Bellingham, Wash.)|January 4, 2018
Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIALAdam Olshen, Denise Wolf, Ella F Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 28, 2021
Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti-PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast CancerPaula I Gonzalez-Ericsson, Julia D Wulfkhule, Rosa I Gallagher, et al.
Blood Advances|October 17, 2017
Microenvironmental agonists generate <i>de novo</i> phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCLKallesh D Jayappa, Craig A Portell, Vicki L Gordon, et al.
NPJ Breast Cancer|October 21, 2020
Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trialDenise M Wolf, Christina Yau, Julia Wulfkuhle, et al.
Plos One|April 28, 2010
Malignant precursor cells pre-exist in human breast DCIS and require autophagy for survivalVirginia Espina, Brian D Mariani, Rosa I Gallagher, et al.
Pageof 3